The extensive utilization of anti-CD38 monoclonal antibodies has led to favorable outcomes, including improved hematologic CR rates, more organ responses (particularly cardiac responses) in AL amyloidosis patients, and even enhanced one-year OS for stage IIIB patients [20,21]. The gene discussed is CD38; the disease is AL amyloidosis.